# **Key Investor Information**

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

# Health Care Innovators, a Subfund of the SICAV BNP Paribas Funds, short named as BNP Paribas

Class "Classic Capitalisation" - ISIN code LU0823416762

This Fund is managed by BNP PARIBAS ASSET MANAGEMENT Luxembourg, part of the BNP Paribas Group

#### Objectives and Investment Policy

The Fund seeks to increase the value of its assets over the medium term by investing in shares issued worldwide by companies which innovate or benefit from healthcare innovation including but not limited to advances in genetic sequencing, drug delivery, miniaturization, bio-compatible materials, haptics and information technology in the healthcare field.


It is actively managed and as such may invest in securities that are not included in the index which is MSCI World Health Care 10/40 (NR).

The investment team applies also BNP PARIBAS ASSET MANAGEMENT Sustainable Investment Policy, which takes into account Environmental, Social and Governance (ESG) criteria in the investments of the Fund.

Income are systematically reinvested.

Investors are able to redeem on a daily basis (on Luxembourg bank business days)

#### Risk and Reward Profile



- Historical data may not be reliable indication for the future.
- The risk category of a Fund is an indicator but not a target or a guarantee and may shift over time.
- The lowest category does not mean a risk-free investment.
- Why is the Fund in this specific category?

The risk category is justified by the investment mainly in Stocks and Shares, the value of which can fluctuate considerably. These fluctuations are often amplified in the short term.

The higher the risk, the longer the recommended investment horizon.

Other risks materially relevant to the Fund which are not adequately captured by the indicator are described below:

 Operational and Custody Risk: Some markets are less regulated than most of the international markets; hence, the services related to custody and liquidation for the subfund on such markets could be more risky.

For more information on risks, please see the "Investment risks" section of the Fund's prospectus, which is available at <a href="https://www.bnpparibas-am.com">www.bnpparibas-am.com</a>.



#### Charges

The charges you pay are used to pay the Fund's running costs, including the costs of marketing and distribution. These charges reduce the potential growth of your investment

One-off charges taken before or after you invest	
Entry charge	3.00%
Exit charge	No
This is the maximum that might be taken out of your money (before the proceeds of your investment are paid out).	
Charges taken from the Fund over each year	
Ongoing charges	1.98%
Charges taken from the fund under specific conditions	
Performance fee	No

The **entry charges** shown are maximum figures. In some cases you might pay less. You can find this out from your financial adviser.

The ongoing charges figure is based on past expenses determined as of 31 October 2020


This figure may vary from year to year. It excludes:

• Portfolio transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling units in another collective investment undertaking. In case of conversion, the investors may be charged a maximum fee of 1.5%.

For more information about charges, please see the "Fees and Costs" section of the Fund's prospectus, which is available at <a href="https://www.bnpparibas-am.com">www.bnpparibas-am.com</a>.

### Past Performance

That year / these years the fund had different characteristics.



2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

- Health Care Innovators Classic
- Benchmark

A: 004/1997-05/2013: Following a corporate action on 17/05/2013, the performanceslisted are the simulated past performance and fees those of the BNP PARIBAS L1 EQUITY WORLD HEALTH CARE. The Sub-Fund BNP PARIBAS FUNDS HEALTH CARE INNOVATORS is managed according to the exact same processes, investment strategy and fees.

- Performance figures are shown for shares classes, for which NAV was continuously calculated during the period from 1st January to 31st December.
- Past performance is not an indicator of future results.
- The ongoing charges of the Fund are included in the calculation of past performance. The entry/exit and conversion fees are excluded from the calculation of the past performance.
- · The share class came into existence in 2013
- · Past performance has been calculated in EUR
- Performance returns are based on the net asset value with distribuable income reinvested.

## Practical information

- Custodian: BNP PARIBAS SECURITIES SERVICES-LUXEMBOURG BRANCH
- Further information about the Fund including the latest Prospectus, latest published prices of share(s), annual report and half yearly report may be obtained free of charge, in English, from BNP PARIBAS ASSET MANAGEMENT Luxembourg or online at <a href="https://www.bnpparibas-am.com">www.bnpparibas-am.com</a>.
- Luxembourg tax legislation may have an impact on the personal tax position of the investor.
- Details of the updated remuneration policy (including a description of how the remuneration and benefits are calculated), the identity of the people responsible for granting the remuneration and benefits and the composition of the remuneration committee are available on the website https://www.bnpparibas-am.com/en/footer/remuneration-policy/. A hard copy of the remuneration policy will be available upon request.
- BNP PARIBAS ASSET MANAGEMENT Luxembourg may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Fund.
- Investors may switch between Funds of BNP Paribas Funds. Please see the prospectus or contact your financial adviser for details.

This Fund is authorised in Grand Duchy of Luxembourg and regulated by the "Commission de Surveillance du Secteur Financier". This key investor information is accurate as at 19 February 2021.

